Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 16/20 | 0.58 |
| ▸ | MMP12 | P39900 | 15/20 | 0.58 |
| ▸ | MMP2 | P08253 | 13/20 | 0.58 |
| ▸ | MMP9 | P14780 | 13/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1839298 | 0.85 | MMP1 (0.44) | MMP1MMP12MMP2MMP9 | |
| SCHEMBL13446064 | 0.85 | MMP2 (0.58) | MMP1MMP12MMP2MMP9MAPT | |
| SCHEMBL12279181 | 0.85 | MMP1 (0.44) | MMP1MMP12MMP2MMP9 | |
| SCHEMBL1838232 | 0.82 | KMT2A (0.47) | MMP1MMP12MMP2MMP9MAPT | |
| SCHEMBL7092540 | 0.78 | MMP1 (0.69) | MMP1MMP12MMP2MMP9 | |
| SCHEMBL1836245 | 0.76 | MMP1 (0.43) | MMP1MMP12MMP2MMP9MAPT | |
| SCHEMBL663552 | 0.71 | KMT2A (0.76) | MMP1MMP12MMP2MMP9MAPT | |
| SCHEMBL1840011 | 0.70 | KDM4E (0.44) | MMP1MMP12MMP2MMP9MAPT | |
| SCHEMBL28939032 | 0.69 | LMNA (0.51) | MAPTLMNA | |
| SCHEMBL9127865 | 0.69 | LMNA (0.55) | MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8795630-B2 | Butyrylcholinesterase ligands as diagnostic tools and treatment for diseases of the nervous system | TREVENTIS CORPORATION (US) | 2014-08-05 | — | — | US | disclosed |
| EP-2320891-B1 | BUTYRYLCHOLINESTERASE LIGANDS AS DIAGNOSTIC TOOLS AND TREATMENT FOR DESEASES OF THE NERVOUS SYSTEM | TREVENTIS CORP (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20110212026-A1 | BUTYRYLCHOLINESTERASE LIGANDS AS DIAGNOSTIC TOOLS AND TREATMENT FOR DESEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION | 2011-09-01 | — | — | US | disclosed |
| EP-2320891-A1 | BUTYRYLCHOLINESTERASE LIGANDS AS DIAGNOSTIC TOOLS AND TREATMENT FOR DESEASES OF THE NERVOUS SYSTEM | Treventis Corporation (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010025368-A1 | BUTYRYLCHOLINESTERASE LIGANDS AS DIAGNOSTIC TOOLS AND TREATMENT FOR DESEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212026-A1 | BUTYRYLCHOLINESTERASE LIGANDS AS DIAGNOSTIC TOOLS AND TREATMENT FOR DESEASES OF THE NERVOUS SYSTEM | BCHE, ACHE, CERS2 | MMP1 445/4885MMP12 2527/4885MMP2 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.